{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:21:07Z","timestamp":1788956467159,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejso.2019.11.499","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T02:20:11Z","timestamp":1573784411000},"page":"684-693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"PA","title":["Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Karan","family":"Rangarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Manas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaed Z.","family":"Hamady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2019.11.499_bib1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJM199910283411807","article-title":"Biliary tract cancers","volume":"341","author":"de Groen","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2019.11.499_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.9-1-43","article-title":"Diagnosis and treatment of cholangiocarcinoma","volume":"9","author":"Anderson","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2019.11.499_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.surg.2012.12.005","article-title":"Recurrence after operative management of intrahepatic cholangiocarcinoma","volume":"153","author":"Hyder","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2019.11.499_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s005340170039","article-title":"Recurrence after surgical resection of intrahepatic cholangiocarcinoma","volume":"8","author":"Yamamoto","year":"2001","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.ejso.2019.11.499_bib5","first-page":"97","article-title":"Detection of circulating tumor cells in cancers of biliary origin","volume":"3","author":"Al Ustwani","year":"2012","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib6","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib7","author":"Network NCCN"},{"issue":"5","key":"10.1016\/j.ejso.2019.11.499_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib9","first-page":"278","volume":"vol. 7","author":"Nakeeb","year":"2005"},{"key":"10.1016\/j.ejso.2019.11.499_bib10","series-title":"Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. Hpb","first-page":"741","volume":"vol. 19","author":"Ghidini","year":"2017"},{"key":"10.1016\/j.ejso.2019.11.499_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejso.2019.11.499_bib12","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejso.2019.11.499_bib13","author":"Wells"},{"key":"10.1016\/j.ejso.2019.11.499_bib14","first-page":"d5928","volume":"vol. 343","author":"Higgins","year":"2011"},{"key":"10.1016\/j.ejso.2019.11.499_bib15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/bjs.7194","article-title":"Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection","volume":"97","author":"de Meijer","year":"2010","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2019.11.499_bib16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00268-006-0218-y","article-title":"Comparison of outcomes following ileostomy versus colostomy for defunctioning colorectal anastomoses","volume":"31","author":"Tilney","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2019.11.499_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s00534-011-0498-y","article-title":"Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors","volume":"19","author":"Murakami","year":"2012","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ejso.2019.11.499_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2010.12.019","article-title":"Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer","volume":"81","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2019.11.499_bib19","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/jgh.12321","article-title":"Adjuvant chemotherapy in resectable cholangiocarcinoma patients","volume":"28","author":"Wirasorn","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2019.11.499_bib20","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s11605-012-1935-1","article-title":"Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins","volume":"16","author":"Glazer","year":"2012","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.ejso.2019.11.499_bib21","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2019.11.499_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.225","article-title":"Gemox versus surveillance following surgery of localized biliary tract cancer: results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial","volume":"35","author":"Edeline","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2019.11.499_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4006","article-title":"Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study","volume":"35","author":"Primrose","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1498-0","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2019.11.499_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/jjco\/hyy004","article-title":"A\u00a0randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT)","volume":"48","author":"Nakachi","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","article-title":"S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study","volume":"62","author":"Furuse","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejso.2019.11.499_bib28","article-title":"Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma","volume":"2017","author":"Luvira","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ejso.2019.11.499_bib29","first-page":"690","article-title":"The global burden of cancer 2013.[erratum appears in","volume":"1","author":"Global Burden of Disease Cancer","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib30","series-title":"Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer control","author":"Massarweh","year":"2017"},{"key":"10.1016\/j.ejso.2019.11.499_bib31","first-page":"21","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"1","author":"Bragazzi","year":"2012","journal-title":"Transl Gastrointest Cancer"},{"key":"10.1016\/j.ejso.2019.11.499_bib32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.ejso.2019.11.499_bib33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bpg.2015.02.003","article-title":"Epidemiology of cholangiocarcinoma","volume":"29","author":"Bergquist","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ejso.2019.11.499_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MOG.0b013e3282fbf9b3","article-title":"Cholangiocarcinoma: lessons from Thailand","volume":"24","author":"Sripa","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.ejso.2019.11.499_bib35","first-page":"363","article-title":"Cholangiocarcinoma: risk factors and clinical presentation","volume":"14","author":"Gatto","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejso.2019.11.499_bib36","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejso.2019.11.499_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24351","article-title":"Risk factors for cholangiocarcinoma","volume":"54","author":"Tyson","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2019.11.499_bib38","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/89.15.1132","article-title":"Epidemiologic aspects of gallbladder cancer: a case-control study of the search program of the international agency for research on cancer","volume":"89","author":"Zatonski","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejso.2019.11.499_bib39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/10.suppl_4.S308","article-title":"Risk factors for biliary tract carcinogenesis","volume":"10","author":"Chapman","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib40","article-title":"BBC01- BBC: phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with locally advanced \/ borderline resectable proximal biliary tract cancer","author":"Culshaw","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejso.2019.11.499_bib41","unstructured":"Title: Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced biliary tract cancers Short Title\/acronym: ABC-07."},{"key":"10.1016\/j.ejso.2019.11.499_bib42","series-title":"New horizons for precision medicine in biliary tract cancers","first-page":"943","author":"Valle","year":"2017"},{"key":"10.1016\/j.ejso.2019.11.499_bib43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2019.11.499_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.3_suppl.285","article-title":"Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets","volume":"33","author":"Holcombe","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib45","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","article-title":"Genetics of biliary tract cancers and emerging targeted therapies","author":"Hezel","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejso.2019.11.499_bib47","article-title":"Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations","volume":"33","author":"Ross","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejso.2019.11.499_bib49","doi-asserted-by":"crossref","first-page":"e1004135","DOI":"10.1371\/journal.pgen.1004135","article-title":"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma","volume":"10","author":"Borad","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ejso.2019.11.499_bib50","first-page":"3838","volume":"vol. 122","author":"Javle","year":"2016"},{"key":"10.1016\/j.ejso.2019.11.499_bib51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-016-3089-4","article-title":"TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer","volume":"78","author":"Ferraro","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejso.2019.11.499_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2017.12.028","article-title":"PICCA study: panitumumab in combination with cisplatin\/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study","volume":"92","author":"Vogel","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2019.11.499_bib53","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A\u00a0KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejso.2019.11.499_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879831931443X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879831931443X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:33:19Z","timestamp":1760059999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879831931443X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S074879831931443X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.11.499","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.11.499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}